Related Experiment Video

Updated: Aug 15, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

[Role of beta-adrenoceptor antagonists in the control of kindling models in rats]

W Yue1, F Zhang, L Wang

  • 1Department of Pharmacology, Medical School of Qingdao University, Qingdao 266021, China.

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|February 6, 2003
PubMed
Abstract

Insights

Central beta 1-adrenoceptors (beta 1-AR) inhibit seizure development in rat kindling models. Beta-AR antagonists like propranolol and metoprolol show anticonvulsant effects, highlighting beta 1-AR

Area of Science:

  • Neuropharmacology
  • Epilepsy research

Context:

  • The study investigates the role of beta-adrenoceptors (beta-AR) in seizure control.
  • Kindling models, including electrical amygdala kindling and pentylenetetrazol (PTZ) kindling in rats, are utilized.
  • Maximal electroshock (MES) in mice is also employed to assess anticonvulsant properties.

Purpose:

  • To elucidate the specific role of beta-adrenoceptor subtypes in the modulation of seizure activity within established kindling models.
  • To evaluate the efficacy of beta-AR agonists and antagonists in altering seizure thresholds and severity.

Summary:

  • Beta-adrenoceptor antagonists, propranolol and metoprolol, demonstrated significant anticonvulsant effects, delaying kindling development, increasing afterdischarge thresholds, and reducing seizure severity in rat models.
  • Selective beta 1-AR agonist dobutamine reversed propranolol's inhibitory effects, whereas beta 2-AR agonist terbutaline had no significant impact, indicating a specific role for beta 1-AR.
  • Metoprolol also exhibited anticonvulsant activity in the MES model in mice.

Impact:

  • Provides evidence for the involvement of central beta 1-adrenoceptors in the inhibitory mechanisms controlling seizure progression in kindling models.
  • Suggests potential therapeutic targets for epilepsy treatment by modulating beta 1-AR activity.

More Related Videos

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...